Literature DB >> 7854543

Myasthenia gravis during interferon alfa therapy.

A P Batocchi1, A Evoli, S Servidei, M T Palmisani, F Apollo, P Tonali.   

Abstract

Patients treated with interferon alfa can develop autoantibodies and autoimmune diseases. We describe two patients who developed myasthenia gravis with abnormal levels of serum anti-acetylcholine receptor antibodies during interferon alfa-2b treatment for malignancies. One of these patients had myopathic findings on EMG and focal deficiency of cytochrome c oxidase on muscle biopsy.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7854543     DOI： 10.1212/wnl.45.2.382

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

3.  Low dose interferon-alpha is safe in patients with myasthenia gravis.

Authors:  H Bolay; R Karabudak; K Varli; O Saribas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

4.  Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment.

Authors:  G Piccolo; D Franciotta; M Versino; E Alfonsi; M Lombardi; G Poma
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

Review 5.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

6.  Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Authors:  Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

Review 7.  New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: A case report and literature review.

Authors:  Tsubasa Takizawa; Marenori Kojima; Shigeaki Suzuki; Takashi Osada; Satoshi Kitagawa; Jin Nakahara; Shinichi Takahashi; Norihiro Suzuki
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

Review 8.  Regulatory T cells in multiple sclerosis and myasthenia gravis.

Authors:  K M Danikowski; S Jayaraman; B S Prabhakar
Journal:  J Neuroinflammation       Date:  2017-06-09       Impact factor: 8.322

9.  Association of polycythemia vera with positive JAK2V617F mutation and myasthenia gravis: A report of two cases.

Authors:  Sreethish Sasi; Mohamed A Yassin; Sadat Kamran; Vazgen Mnatsakanyan
Journal:  Clin Case Rep       Date:  2020-11-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.